Loading stock data…
$162.40+6.56 (+4.21%)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AstraZeneca PLC in the Healthcare sector is trading at $162.40 with a market capitalization of $251.9B. Wall Street consensus targets $207.16 (12 analysts), implying a +27.6% move over the next 12 months. The stock is currently near its 52-week low of $153.41, remaining 10.2% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.38B↑ | $15.29B↓ | $15.50B↑ | $15.19B↑ | $14.46B |
| Gross Profit | $12.86B↑ | $12.61B↑ | $12.38B | $12.39B↑ | $11.98B |
| Operating Income | $3.16B↓ | $4.25B↑ | $2.98B↓ | $3.58B↑ | $3.51B |
| Net Income | $2.51B↓ | $3.08B↑ | $2.33B↓ | $2.53B↑ | $2.45B |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...